Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Linearis Labs Opens Lab Formerly Occupied by Medicago | Contract Pharma

What are you searching for?

Sign in
Breaking News

Linearis Labs Opens Lab Formerly Occupied by Medicago

Acquired over 650 scientific instruments and hired some of Medicago’s specialized personnel in mass spec, QA, and lab management.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Linearis Labs Inc., a company intersecting AI and biomarker analysis, opened its new laboratory facilities at a site formerly occupied by Medicago Inc. Linearis acquired over 650 scientific instruments and hired some of Medicago’s specialized personnel in mass spectrometry, quality assurance, and laboratory management.
 
The combination of AI and high-throughput automated analysis of 1,400 metabolomic biomarkers enables Linearis to better identify numerous elements associated with metabolic diseases including cancer, diabetes, and antimicrobial resistance. This global approach aims to improve prevention, screening, treatment monitoring, and drug discovery. Linearis’ analytical services cater to biobanks, researchers, clinical research organizations, and biopharmaceutical companies.
 
“We are grateful for the support from Medicago during this transaction enabling the creation of this innovative and collaborative laboratory. The identification of disease signatures not only makes prevention accessible, but it also contributes to improving the prevention, screening, discovery of treatments, and acceleration of precision medicine,” said Alexandre Le Bouthillier, President and CEO of Linearis.
 
“We wish the laboratory instruments acquired by Linearis as a part of our wind-up process, contribute to the advancements in biotechnology and AI while bearing the fruits of a healthy future accessible to all,” said Toshifumi Tada, President and CEO of Medicago.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics